Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
Open accessThe DOI matches its Crossref record; 75 of the 79 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cyclin-dependent kinases (CDKs) regulate cell proliferation and coordinate the cell cycle checkpoint response to DNA damage. Although inhibitors with varying selectivity to specific CDK family members have been developed, selective CDK4/6 inhibitors have emerged as the most attractive antineoplastic agents because of the importance of CDK4/6 activity in regulating cell proliferation and the toxic effects associated with inhibition of other CDKs (eg, CDK1 and CDK2). METHODS: FVB/N wild-type mice (n = 13) were used to evaluate carboplatin-induced myelosuppression in bone marrow by complete blood cell counts after treatment with the CDK4/6 inhibitor PD0332991. Genetically engineered murine models of retinoblastoma (Rb)-competent (MMTV-c-neu) and Rb-incompetent (C3-TAg) breast cancer (n = 16 MMTV-c-neu mice in the carboplatin plus vehicle control group, n = 17 MMTV-c-neu mice in the carboplatin plus PD0332991 group, n = 17 C3-TAg mice in the carboplatin plus vehicle control group, and n = 14 C3-TAg mice in the carboplatin plus PD0332991 group) were used to investigate the antitumor activity of PD0332991 alone or in combination with chemotherapy. All statistical tests were two-sided. RESULTS: Coadministration of PD0332991 with carboplatin compared with carboplatin alone in FVB/N wild-type mice increased hematocrit (51.2% vs 33.5%, difference = 17.7%, 95% confidence interval [CI] = -26.7% to -8.6%, P < .001), platelet counts (1321 vs 758.5 thousand cells per μL, difference = 562.5 thousand cells per μL, 95% CI = -902.8 to -222.6, P = .002), myeloid cells (granulocytes and monocytes; 3.1 vs 1.6 thousand cells per μL, difference = 1.5 thousand cells per μL, 95% CI = -2.23 to -0.67, P < .001), and lymphocytes (7.9 vs 5.4 thousand cells per μL, difference = 2.5 thousand cells per μL, 95% CI = -4.75 to -0.18, P = .02). Daily administration of PD0332991 exhibited antitumor activity in MMTV-c-neu mice as a single agent. However, the combination of carboplatin plus PD0332991 decreased antitumor activity compared with carboplatin alone in Rb-competent mice (mean percent change in tumor volume at day 21 = -52.6% vs 3.7% for carboplatin and carboplatin plus PD0332991, respectively, difference = 56.3%, 95% CI = -109.0% to -3.6%, P = .04). In contrast, Rb-deficient tumors in C3-Tag mice were resistant to PD0332991, and coadministration of PD0332991 plus carboplatin had no effect on in vivo tumor growth (mean percent change in tumor volume at day 21 = 118.8% and 109.1% for carboplatin and carboplatin plus PD0332991, respectively, difference = 9.7%, 95% CI = -183.5% to 202.9%, P = .92). Finally, in tumor-bearing mice, coadministration of PD0332991 with carboplatin provided statistically significant protection of platelets (P = .04). CONCLUSION: We believe that the present data support a possible role for CDK4/6 inhibitors in a majority of patients with advanced cancer: to either inhibit tumor growth in CDK4/6-dependent tumors or ameliorate the dose-limiting toxicities of chemotherapy in CDK4/6-indepdendent tumors. Our data also suggest CDK4/6 inhibitors should not be combined with DNA-damaging therapies, such as carboplatin, to treat tumors that require CDK4/6 activity for proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in a mouse RB-competent MMTV-HER2-driven breast cancer model, the anti-tumor activity of carboplatin was compromised by palbociclib administration, whereas in an RB-deficient model, palbociclib co-administration protected against carboplatin-induced hematologic toxicity (129).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Self-citationCell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 2×
“There are four proliferative CDKs: CDK1, which predominantly regulates the transition from G2 to M phase, and CDK2/4/6, which regulate the transition from G1 to S phase (1,2).”
BackgroundMethodGiaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,461
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,285
Self-citationHenke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Cited by
Items 201–274 of 274
Shamieh, S. E., Saleh, F., Assaad, S., & Farhat, F. S. (2019) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2018-0027 · Cited by 9
Zhang, M., Song, J. H., Guo, S., Jin, F., & Zheng, A. (2023) · Endocrine Related Cancer · doi:10.1530/erc-22-0365 · Cited by 9
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
Knudsen, E. S., Witkiewicz, A. K., & Kabraji, S. K. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01431-5 · Cited by 9
Nekova, T. S., Kneitz, S., Einsele, H., Bargou, R. C., & Stuhler, G. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1241915 · Cited by 8
Son, K.-H., Kim, M.-Y., Shin, J.-Y., Kim, J.-O., & Kang, J.-H. (2021) · Anticancer Research · doi:10.21873/anticanres.15296 · Cited by 8
Kempisty, B., Ziółkowska, A., PIOTROWSKA, H., Antosik, P., Bukowska, D., Zawierucha, P., Jaśkowski, J. M., Brüssow, K. ‐., Nowicki, M. O., & Zabel, M. (2013) · Acta Veterinaria Hungarica · doi:10.1556/avet.2013.039 · Cited by 8
Perrone, M., Giuliani, F., Sanna, V., Bruno, S., Melaccio, A., Santoro, A. N., Laface, C., Maselli, F. M., Iaia, M. L., Guarini, C., et al. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2201373 · Cited by 7
Advances in the approach to novel drug clinical development for breast cancer
Ferrario, C., & Batist, G. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.911282 · Cited by 6
Vassiliki, T., Gogadis, A., Christos, A., & Timotheadou, E. T. (2019) · Forum of Clinical Oncology · doi:10.2478/fco-2019-0007 · Cited by 6
Pearson, A. D. J., Chi, S. N., Laetscht, T. W., Marshall, L. V., Raetz, E. A., George, R. E., Chesler, L., Karres, D., Scobie, N., Knoderer, H. M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115629 · Cited by 6
Shi, W., Wang, R., Qian, J., Wang, L., Li, Y., Mi, Y., Jia, Z., Pan, M., Zhang, X., Ye, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02080 · Cited by 6
Patel, T. I., Joshi, J. N., Valvezan, A. J., & Moschitto, M. J. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03288-y · Cited by 6
Cyclin Kinase Inhibitors in Breast Cancer: From Bench to Bedside
Torres, G., Echavarría, I., Lobo, M., Márquez‐Rodas, I., & Martín, M. (2014) · Current Breast Cancer Reports · doi:10.1007/s12609-014-0142-3 · Cited by 5
Wang, X., Li, C., Li, C., Qin, M., Wu, J., Qin, Y., Zou, Y., Zeng, H., Li, C., Huang, X., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1600892 · Cited by 5
Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
Mangal, S., Debnath, A., Mazumder, R., Mazumder, A., Singh, R. K., Sanchitra, J., Jan, S. K. A., Pandey, P., Kumar, B., & Singh, A. K. (2024) · All Life · doi:10.1080/26895293.2024.2417192 · Cited by 5
Wieser, R. (2012) · Cell Cycle · doi:10.4161/cc.22392 · Cited by 5
Cheng, Q., Shi, X., Zhao, Y., Zou, S., & Sun, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2338247 · Cited by 5
Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers
Mir, M. A., & Jan, U. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_10 · Cited by 4
Improving Breast Cancer Therapy With CDK4/6 Inhibitors
Jaganathan, H., Overstreet, K. A., & Reed, E. C. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.10.001 · Cited by 4
Retinoblastoma protein determines aggressiveness in triple-negative breast cancer
Jacob, J., Frampton, A. E., Castellano, L., Stebbing, J., & Krell, J. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.31 · Cited by 3
SİKLİN BAĞIMLI KİNAZ 4/6 VE İNHİBİTÖRLERİ
Arslan, G., Önkol, T., & Özçelik, A. B. (2022) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.978763 · Cited by 3
Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer
Syn, N. L. X., Wee, I. J. Y., Wong, A. L.-A., Goh, R. M., Ow, S. G. W., Lambertini, M., & Lee, S. C. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012919 · Cited by 3
Wang, X., Lin, X., Liu, Y., Ma, C., Liu, M., Bai, J., Ye, Y., Zhao, C., Yang, L., Huang, X., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102382 · Cited by 3
UnCHKed DNA replication: A stressful matter
Gryp, J. L., & Gutierrez, G. J. (2012) · Cell Cycle · doi:10.4161/cc.22394 · Cited by 3
ORCA is regulated by ubiquitin-mediated degradation to control Orc2 function
Ikui, A. E. (2012) · Cell Cycle · doi:10.4161/cc.22391 · Cited by 3
Cyclin-Dependent 4/6 Kinase Inhibitors for Treatment of HER2-Positive Breast Cancer: 2026 Update
O'Sullivan, C. C. (2026) · Cancers · doi:10.3390/cancers18030533 · Cited by 3
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
Chinea, L. E., Hauer, C., Pal, K., Chang, H. L., & Chan, I. S. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01232-1 · Cited by 2
Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies
Alexander, A., & Keyomarsi, K. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-8039-6_14 · Cited by 2
Chaudhuri, T., Babu, G., Lakshmaiah, K., Dasappa, L., Jacob, L. A., Babu, M. S., Rudresha, A. H., Lokesh, K. N., & Rajeev, L. (2019) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_87_18 · Cited by 2
Chen, W., Zhou, L., Jiang, J., Chen, J., Geng, D., Chen, Y., Han, X., Xie, Q., Guo, G., Chen, X., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04179-8 · Cited by 2
Addicted to PAR? A closer look at PARP inhibitor sensitivity
Altmeyer, M. (2012) · Cell Cycle · doi:10.4161/cc.22393 · Cited by 2
Novel predication of protein biomarkers in interferon-gamma-stimulated breast cancer cells.
Ssadh, H. A., & Abdulmonem, W. A. (2019) · PubMed Central · Cited by 2
Management of Hormone Receptor-Positive Metastatic Breast Cancer
Chiu, J. W. Y. (2018) · IntechOpen eBooks · doi:10.5772/intechopen.75759 · Cited by 2
Twenty-First Century Pathology Sign-Out
Tomlins, S. A., Robinson, D., Penny, R. J., & Hess, J. L. (2012) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2012.07.002 · Cited by 2
NEW PHARMACOLOGICAL APPROACHES IN THE TREATMENT OF ONCOLOGICAL DISEASES
Georgiev, K., & Georgieva, M. (2015) · Journal of IMAB - Annual Proceeding (Scientific Papers) · doi:10.5272/jimab.2015213.818 · Cited by 2
Yuan, K., Chen, W., Wang, X., & Yang, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00022-4 · Cited by 1
Yang, Y., Zhu, S., Fu, Z., Sun, C., Yang, F., Zeng, T., Hua, Y., Bao, S., Gao, X., Huang, X., et al. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-54 · Cited by 1
The FANCA to FANCZ of DNA interstrand crosslink repair: Lessons from Fanconi anemia
O’Rourke, J. J., & Deans, A. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00012-7 · Cited by 1
Бесова, Н. С. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-9-27-42 · Cited by 1
Targeting the CDK4/6 Pathway in Breast Cancer
Malorni, L., Migliaccio, I., Guarducci, C., Bonechi, M., & Leo, A. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_69 · Cited by 1
The Cyclin D/Cyclin-dependent Kinase 4/6 Complex as a Target in the Treatment of Breast Cancer
Clark, A. S., & DeMichele, A. M. (2015) · Current Breast Cancer Reports · doi:10.1007/s12609-015-0189-9 · Cited by 1
Development of fluorescent biosensors and inhibitors to probe and target CDK4/cyclin D in melanoma
Prével, C. (2015) · theses.fr (ABES) · doi:10.70675/acc45705z7b44z4fe2zbc0ez866d13764616 · Cited by 1
Thacker, U. (2017) · Lancaster EPrints (Lancaster University) · doi:10.17635/lancaster/thesis/148 · Cited by 1
Lai, G.-Y., Chan, H., Chen, T.-C., Lee, W.-J., & Ho, Y. S. (2022) · Journal of Cancer Research and Practice · doi:10.4103/jcrp.jcrp_11_21 · Cited by 1
Antitumorska i antimikrobna aktivnost novosintetisanih kompleksa platine (II) i paladijuma (II)
Zornić, S. (2024) · National Repository of Dissertations in Serbia · Cited by 1
Senescence in Oncogenesis: From Molecular Mechanisms to Therapeutic Opportunities
Muñoz-Galván, S., & Carnero, A. (2014) · Springer eBooks · doi:10.1007/978-94-017-9421-3_7
Ramos, J. D. (2018) · FIU - Digital Commons (Florida International University) · doi:10.25148/etd.fidc007034
Erratum to: Frontiers in Wastewater Treatment and Modelling
Mannina, G. (2017) · Lecture notes in civil engineering · doi:10.1007/978-3-319-58421-8_116
Targeting WEE1 in diffuse large B-cell lymphoma: mediator in DNA damage and apoptosis
de Jong, M. R. W. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.119647288
CDK4/6 inhibitors for the treatment of breast cancer
Ayush, S., Snehal, P., Singh, R. M., & Kumar, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33653-9.00008-9
Cyclin D1-AR Crosstalk: Potential Implications for Therapeutic Response in Prostate Cancer
Schiewer, M. J. (2012) · Defense Technical Information Center (DTIC) · doi:10.21236/ada564541
Caracterització de l'efecte de compostos naturals en models in vitro i in vivo de càncer de còlon
Tena, S. S. (2012) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Wang, C., Zhang, Y., Bao, S., Huang, X., Wang, C., & Zhang, Y. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110565
Pfefferle, A. D. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/6bg2-dy11
Découverte de biomarqueurs prédictifs en cancer du sein par intégration transcriptome-interactome
Garcia, M. (2013) · theses.fr (ABES) · doi:10.70675/118a1aa0zabe2z417dz866fz3c56693a7dc3
Woong, S. J., Lee, S. Y., Kim, C. H., & Park, J. Y. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-1903
Davis, L. E., Zhu, L., Latour, E. J., McMahon, N. P., Nishikawa, G., Choo, F., Nusser, K. D., Pittsenbarger, J., Burch, R., Park, B. S., et al. (2025) · doi:10.1158/1078-0432.29444336
Huang, Y., Wu, H., & Li, X. (2020) · Figshare · doi:10.6084/m9.figshare.13083378
Huang, Y., Wu, H., & Li, X. (2020) · Figshare · doi:10.6084/m9.figshare.13083375
Cai, Y., Zhang, J., Duan, H., & Liu, F. (2025) · Oncology Letters · doi:10.3892/ol.2025.14973
Proliferation Markers in Breast Cancer
Penault-Llorca, F. M., & Radosevic‐Robin, N. (2016) · Springer eBooks · doi:10.1007/978-3-319-41761-5_7
Importance de la voie Cdk4-EZH2 dans l'échappement à la sénescence induite par la chimiothérapie
Gouju, J. (2016) · theses.fr (ABES) · doi:10.70675/be4fffa5zf97az4809z86f7z687238fb7187
Baker, A. T. (2017) · Loyola eCommons (Loyola University of Chicago)
Duan, S.-Y., Lin-hui, Z. H. A. I., Zhang, W., Luo-yi, C., Rui-xi, Z., Zou, X., Ni, J.-H., Jia, X., Liu, T., Fu, H., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01858-x
Huang, L., Lin, T., Jiang, S., Lin, A., Zhu, Y., Lin, Z., Lin, Y., & Su, S. (2026) · Nutrients · doi:10.3390/nu18162670
Salvador-Barberó, B. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Optimizing cell-free DNA analyses to improve breast cancer care
Jongbloed, L. (2025) · EUR Research Repository (Erasmus University Rotterdam)
Role autoprotilátek v boji proti nádorům
Štěpařová, K. (2021) · Digital library - University of Pardubice (University of Pardubice)
Garcia, M. A. D. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Identifying Targetable Liabilities in Ewing Sarcoma
Vallurupalli, M. (2014) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Borella, F., Cosma, S. D., Gallio, N., Dragone, G., Arridu, S., Cappella, G., Hotot, M., Battista, E., Cassoni, P., & Castellano, I. (2026) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2026.084204
S. A. Jadhav, A. R. S., Shinde, A. R., & Surale-Patil, S. A. (2023) · Journal of chemical health risks
Metadata
- Authors
- Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-02-01
- Volume
- 104
- Issue
- 6
- Pages
- 476-487
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC3309128
- OpenAlex
- W2132726386
- Cited by
- 255
- References
- 79
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 8 · 2023: 10 · 2022: 17 · 2021: 10 · 2020: 26 · 2019: 17 · 2018: 21 · 2017: 25 · 2016: 27 · 2015: 26 · 2014: 25 · 2013: 17 · 2012: 7
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- American Cancer Society
- Burroughs Wellcome Fund
- Ellison Medical Foundation
- Golfers Against Cancer
- National Institutes of Health (5r01ag024379-15, ES014635, RO1 P01-ES014635, CA58223, P50-CA58223-09A1)
- National Institute on Aging (R01-AG024379)
- National Cancer Institute (P50‐CA58223‐09A1, R01CA166480, R01CA122794, R01CA140594, UO1-CA141576, R01CA163896, P50CA058223, R01CA148761, P30CA016086, U01CA141576)
- National Institute of Environmental Health Sciences (P01ES014635, R01 P01-ES014635)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6 inhibitors, palbociclib, carboplatin, myelosuppression, hematologic toxicity, retinoblastoma, breast cancer, combination chemotherapy, anticancer activity, cell cycle checkpoints, DNA damage response
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Blood Platelets, Breast Neoplasms, DNA Damage, DNA, Neoplasm, Doxorubicin, Enzyme Activation, Female, Flow Cytometry, Piperazines, Pyridines, Retinoblastoma, Carboplatin, Apoptosis, Erb-b2 Receptor Tyrosine Kinases, Protective Agents, Caspases, Protein Kinase Inhibitors, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, G1 Phase Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.